Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 18/20 | 0.70 |
| ▸ | MGLL | Q99685 | 18/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425789 | 1.00 | FAAH (0.70) | FAAHMGLLGAACYP2C9CYP2C19 | |
| SCHEMBL425580 | 0.98 | FAAH (0.72) | FAAHMGLL | |
| SCHEMBL19357103 | 0.92 | FAAH (0.81) | FAAHMGLL | |
| SCHEMBL427533 | 0.87 | MGLL (0.62) | FAAHMGLL | |
| SCHEMBL427313 | 0.85 | MGLL (0.63) | FAAHMGLL | |
| SCHEMBL426681 | 0.85 | MGLL (0.71) | FAAHMGLL | |
| SCHEMBL427310 | 0.85 | MGLL (0.71) | FAAHMGLL | |
| SCHEMBL426951 | 0.85 | FAAH (0.71) | FAAHMGLL | |
| SCHEMBL5640342 | 0.84 | FAAH (0.62) | FAAHMGLL | |
| SCHEMBL424467 | 0.84 | FAAH (0.62) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885MGLL 11/4885GAA 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.